BioNTech SE Sponsored ADR (NASDAQ:BNTX) Stake Reduced by Scotia Capital Inc.

Key Points

• Scotia Capital Inc. reduced its stake in BioNTech SE by 37.2%, selling 65,143 shares and now holding 110,081 shares valued at approximately $10 million.
• Several institutional investors increased their positions, with Bank of New York Mellon Corp growing its stake by 18,892.9% in the first quarter.
• Wall Street analysts have mixed sentiments, with a consensus rating of "Moderate Buy" and a target price of $136.58 for BioNTech stock.

Scotia Capital Inc. trimmed its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 37.2% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 110,081 shares of the company's stock after selling 65,143 shares during the quarter. Scotia Capital Inc.'s holdings in BioNTech were worth $10,024,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. FMR LLC increased its position in BioNTech by 22.2% in the 4th quarter. FMR LLC now owns 7,701,476 shares of the company's stock valued at $877,583,000 after acquiring an additional 1,401,547 shares during the period. Bank of New York Mellon Corp grew its position in BioNTech by 18,892.9% in the 1st quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company's stock valued at $63,593,000 after buying an additional 694,691 shares in the last quarter. BNP Paribas Financial Markets bought a new position in BioNTech in the 4th quarter valued at about $69,999,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its position in shares of BioNTech by 632.6% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 501,897 shares of the company's stock worth $57,191,000 after buying an additional 433,388 shares in the last quarter. Finally, Capital International Investors lifted its stake in shares of BioNTech by 38.6% in the 4th quarter. Capital International Investors now owns 1,415,566 shares of the company's stock worth $161,304,000 after acquiring an additional 394,434 shares during the period. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Stock Down 0.1%

BNTX stock opened at $107.34 on Monday. The company has a 50 day moving average of $108.11 and a two-hundred day moving average of $106.17. The company has a market cap of $25.80 billion, a price-to-earnings ratio of -31.57 and a beta of 1.23. BioNTech SE Sponsored ADR has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a quick ratio of 10.02, a current ratio of 10.18 and a debt-to-equity ratio of 0.01.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. The Goldman Sachs Group started coverage on shares of BioNTech in a report on Thursday, May 29th. They issued a "neutral" rating and a $110.00 price target for the company. Morgan Stanley raised their target price on shares of BioNTech from $132.00 to $133.00 and gave the stock an "overweight" rating in a report on Thursday, July 10th. Leerink Partners set a $112.00 price target on BioNTech in a report on Monday, June 2nd. HC Wainwright reiterated a "buy" rating and set a $138.00 price objective on shares of BioNTech in a research report on Wednesday, June 25th. Finally, Wall Street Zen upgraded BioNTech from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $136.58.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.